Dapagliflozin vs vitamin E against NAFLD with type 2 DM
Not Applicable
- Conditions
- onalcoholic fatty liver disease Nonalcoholic steatohepatitNAFLD NASH type 2 DM
- Registration Number
- JPRN-jRCT1031180386
- Lead Sponsor
- Ikejima Kenichi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
HbA1c>=6.5% after dietary exercise during pre-observation period (8 to 16 weeks), hepatic steatosis in abdominal US
Exclusion Criteria
1.ethanol consumption over 30g/d in Male or 20g/d in Female
2.type 1 diabetic patients
3. poor glycemic control HbA1c>=8.4%
4.patients who are being treated for liver disease other than NAFLD
5.Male: serum creatinine higher than 1.2mg/dL Female: serum creatinine higher than 1.0mg/dL patients
6.Patients who cannot be aware of dry mouth
7.SGLT2 inhibitor contraindication case
8.Patients with a history of hypersensitivity to SGLT2 inhibitor/Vit. E
9.Patients judged to be ineligible by a doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method